Robert J Gould has sold FULC and made no open-market buys since Feb 2020
Director at Fulcrum Therapeutics, Inc.
SEC CIK 0001577034 · Filings on SEC.gov ↗
$0Bought
$4.6MSold
NoneLast buy
Every filing
17 filings since Feb 2020, newest first
FULCSell
Fulcrum Therapeutics, Inc.
Director
$178K−3.0%Jan 6
FULCSell
Fulcrum Therapeutics, Inc.
Interim Pres, CEO
$101K−1.0%Jan 13
FULCSell
Fulcrum Therapeutics, Inc.
Director
$578K−12.0%Jun 8
FULCSell
Fulcrum Therapeutics, Inc.
Director
$533K−12.0%Jun 6
FULCSell
Fulcrum Therapeutics, Inc.
Director
$135K−1.0%Apr 11
FULCSell
Fulcrum Therapeutics, Inc.
Director
$2.3M−16.0%Apr 5
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$122K−2.0%Mar 17
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$117K−2.0%Feb 18
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$121K−2.0%Jan 22
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$50KJul 9
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$52KJun 26
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$69K−1.0%Jun 9
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$56K−1.0%Jun 5
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$56K−1.0%Jun 3
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$66K−1.0%Jun 1
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$50KMay 28
FULCSell
Fulcrum Therapeutics, Inc.
Insider
$50KFeb 20
Filings come from SEC EDGAR. Not investment advice.